Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AGIO |
---|---|---|
09:32 ET | 3989 | 45.14 |
09:36 ET | 36100 | 45.26 |
09:38 ET | 700 | 45.22 |
09:39 ET | 868 | 45.19 |
09:41 ET | 2669 | 45.405 |
09:43 ET | 200 | 45.41 |
09:45 ET | 2264 | 45.395 |
09:48 ET | 3203 | 45.84 |
09:50 ET | 1380 | 45.745 |
09:52 ET | 500 | 45.75 |
09:54 ET | 200 | 45.72 |
09:56 ET | 900 | 45.61 |
09:57 ET | 1300 | 45.575 |
09:59 ET | 707 | 45.58 |
10:01 ET | 200 | 45.595 |
10:03 ET | 2372 | 45.37 |
10:06 ET | 1500 | 45.71 |
10:08 ET | 900 | 45.7 |
10:10 ET | 100 | 45.75 |
10:12 ET | 1900 | 45.745 |
10:14 ET | 876 | 45.71 |
10:15 ET | 2179 | 45.93 |
10:17 ET | 100 | 45.94 |
10:19 ET | 2543 | 46 |
10:21 ET | 5183 | 45.95 |
10:24 ET | 400 | 46.005 |
10:26 ET | 500 | 46 |
10:28 ET | 300 | 46 |
10:30 ET | 4506 | 46.03 |
10:32 ET | 533 | 46.03 |
10:33 ET | 100 | 46.07 |
10:35 ET | 2935 | 46.1137 |
10:37 ET | 630 | 46.105 |
10:39 ET | 585 | 46.05 |
10:42 ET | 100 | 46.03 |
10:44 ET | 200 | 46.1181 |
10:46 ET | 36180 | 45.79 |
10:50 ET | 200 | 45.67 |
10:51 ET | 909 | 45.61 |
10:53 ET | 8928 | 45.47 |
10:55 ET | 700 | 45.765 |
10:57 ET | 778 | 45.77 |
11:00 ET | 400 | 45.765 |
11:02 ET | 300 | 45.705 |
11:04 ET | 2847 | 45.625 |
11:06 ET | 2897 | 45.72 |
11:08 ET | 100 | 45.7 |
11:09 ET | 1449 | 45.77 |
11:11 ET | 100 | 45.77 |
11:13 ET | 1500 | 45.785 |
11:15 ET | 200 | 45.74 |
11:20 ET | 100 | 45.83 |
11:22 ET | 200 | 45.79 |
11:24 ET | 39347 | 46.005 |
11:26 ET | 900 | 46.125 |
11:27 ET | 4543 | 45.94 |
11:29 ET | 1327 | 45.945 |
11:31 ET | 100 | 45.91 |
11:33 ET | 300 | 45.902 |
11:36 ET | 2936 | 45.83 |
11:38 ET | 6899 | 45.89 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Agios Pharmaceuticals Inc | 2.7B | -7.1x | --- |
Janux Therapeutics Inc | 2.6B | -50.7x | --- |
Geron Corp | 2.7B | -12.6x | --- |
SpringWorks Therapeutics Inc | 2.8B | -7.3x | --- |
Protagonist Therapeutics Inc | 2.8B | 17.1x | --- |
Immunitybio Inc | 2.5B | -4.1x | --- |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $31.3M |
Shares Outstanding | 56.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-6.49 |
Book Value | $14.50 |
P/E Ratio | -7.1x |
Price/Sales (TTM) | 84.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,293.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.